Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Dr. Reddy's Laboratories inks agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC

Posted On: 2019-06-14 09:18:18

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy's would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRA™ (sumatriptan nasal spray) 10 mg, (formerly referred to as "DFN-02"), which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.

Under the agreement, Dr.Reddy's will receive U.S.$70 million as upfront consideration, U.S.$40.5 million in near term milestones and additional financial considerations including, existing contractual obligation and inventory. Subsequently, Dr. Reddy's will receive sales based royalties on a quarterly basis.

The closing of the transaction is subject to various customary closing conditions including antitrust review under Hart-Scott-Rodino Act.

"This is a testament to our strong R&D capabilities, and delivering solutions to unmet needs of patients. In a short time, we created a well-recognized migraine specialty business in the US and we look forward to our partnership with Upsher-Smith" said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy's Laboratories Limited.

"Tosymra and Zembrace were designed and developed with the goal of addressing unmet needs of large but discrete segments of patients suffering from episodic migraine who need options other than their current therapies. We are excited to partner with Upsher-Smith which has established a strong presence in neurology" said Anil Namboodiripad, Ph.D., Senior Vice President, Proprietary Products and Head, Promius Pharma.

Important Patient Safety Information for Zembrace SymTouch (sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg.

Zembrace SymTouch and TOSYMRA can cause serious side effects, including: heart attack and other heart problems, which may lead to death.

Do not use Zembrace SymTouch and TOSYMRA if you have:

- heart problems or a history of heart problems
- narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
- uncontrolled high blood pressure
- severe liver problems
- hemiplegic migraines or basilar migraines. If you are not sure if you have these, ask your healthcare provider,
- had a stroke, transient ischemic attacks (TIAs), or problems with your blood circulation
- taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your healthcare provider if you are not sure if your medicine is listed above
- are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.
- an allergy to sumatriptan or any of the ingredients in Zembrace SymTouch and TOSYMRA.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2586.15 as compared to the previous close of Rs. 2590.35. The total number of shares traded during the day was 23020 in over 1512 trades.

The stock hit an intraday high of Rs. 2601.3 and intraday low of 2559.65. The net turnover during the day was Rs. 59339250.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Granules India Limited receives US FDA approval for Fexofenadine Hydrochloride Tablets

Onmobile enters into partnership with Bharti Airtel to power games on Thanks App

Oberoi Realty Ltd consolidated Q2 net profit slips to Rs.138.07 crore

Subscriber base of RIL's Digital Services Business at 355.2 million as of Sep 30, 2019

Sasken Technologies Ltd reports consolidated EPS of Rs. 13.34 in Q2 FY 2019-20

RIL's Media Business reports robust growth in subscription income

HDFC Bank Limited announces Q2 FY2019-20 results

RIL's revenue from Organized Retail Business up 27% YoY to Rs. 41202 crore in Q2

DCB Bank announces Second Quarter FY 2020 Results

RIL's revenue from Oil and Gas Business declines to Rs. 790 crore in Q2

Cementing a Green Future

RIL's Petrochemicals Business Q2 revenue down 11.9% YoY

Siyaram Silk Mills Ltd Board declares Interim Dividend, onetime special dividend

HDB Financial Services Ltd posts net profit of Rs. 213 crore in Q2

HDFC Securities Limited Q2 PAT at Rs. 91 crore

ICRA reaffirms long term rating of Shalby Limited

Brickwork Ratings reaffirms ratings of Oriental Bank of Commerce

Brickwork Ratings updates on credit ratings of Aarvee Denims & Exports Ltd

ICRA retains credit rating of Z F Steering Gear India Ltd

Shiva Cement Ltd Q2 loss at Rs. 6.22 crore

Bhansali Engineering Polymers Ltd Q2 consolidated net profit at Rs. 20.36 crores

Dalmia Bharat Ltd posts consolidated PAT of Rs. 36 crore in Q2

Siyaram Silk Mills Ltd consolidated Q2 net profit climbs to Rs. 29.31 crore

Avanti Feeds Ltd Q2 consolidated PAT rises to Rs. 118.69 crores

DCB Bank Limited posts net profit of Rs. 91.41 crores in Q2 FY 2019-20

LIC Housing Finance Ltd Q2 consolidated PAT higher at Rs. 768.05 crores

HDFC Bank Ltd reports consolidated Q2 PAT of Rs. 6638.03 crores

Aro Granite Industries Ltd posts slump in Q2 net profit

Jasch Industries Ltd Q2 loss at Rs. 0.60 crore

Chembond Chemicals Ltd consolidated Q2 net profit slides to Rs. 1.52 crore

Shree Cement Ltd consolidated Q2 net profit at Rs. 310.62 crores

Smruthi Organics Ltd Q2 PAT at Rs. 1.89 crore

Menon Bearings Ltd Q2 PAT falls to Rs. 2.93 crore

Pioneer Distilleries Ltd Q2 loss at Rs. 19.91 crore

VTM Ltd reports net profit of Rs. 4.33 crore in Q2 FY 2019-20

National Plastic Technologies Ltd Q2 PAT climbs to Rs. 0.59 crore

RMC Switchgears Ltd is participating in ACETECH - Bengaluru 2019

3P Land Holdings Ltd posts net profit of Rs. 0.22 crore in Q2

RIL's GRM for Q2 stood at $ 9.4/bbl

Mr. Abhishek Sinha appointed as COO & Whole-Time Director of L&T Technology Services Limited

RIL consolidated Q2 PAT at Rs. 11262 crore

L&T Finance Holdings Ltd announces Q2 FY 2019-20 results

L&T Technology Services continues double-digit revenue growth in Q2FY20

Maruti Suzuki India Ltd announces introduction of Regulatory Compliant EECO

ICICI Lombard General Insurance Company Limited announces Q2 FY 2019-20 results

CARE updates on ratings of Indiabulls Housing Finance Ltd

Ambuja Cements Ltd announces Q3 CY2019 results

Digital & Consumer Electronics Brand - Xmate disrupts the Indian market by launching an extensive product portfolio

Brickwork Ratings reaffirms ratings of Punjab National Bank

L&T Technology Services Ltd Board approves Dividend of Rs. 7.50 for 2019-20







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019